Stay updated on Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The NIH-wide announcement about updates to terminology for artificial intelligence was removed from the page.
    Difference
    1%
    Check dated 2026-11-08T13:23:41.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.2 to v3.8.0; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T14:09:17.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to related updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T13:24:36.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T14:07:28.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The site footer’s revision identifier changed from v3.7.0 to v3.7.1; the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-11T14:42:04.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error screen, replacing the usual study details with a basic error layout and site footer.
    Difference
    17%
    Check dated 2026-09-20T12:21:25.000Z thumbnail image

Stay in the know with updates to Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial page.